20 07, 2026

Circulating microRNAs Reveal Molecular Effect of Zoledronic Acid on Tendon-to-Bone Healing

2026-07-20T09:10:58+02:00July 20th, 2026|Biomarker Discovery, biomarkers, microRNA, microRNA services, microRNAs|0 Comments

New publication in the American Journal of Sports Medicine, co-authored by TAmiRNA Retears remain a common complication after arthroscopic rotator cuff repair. A recent study by researchers from the AUVA Trauma Center Vienna-Meidling, the Ludwig Boltzmann Institute for Traumatology, the Austrian Cluster for Tissue Regeneration, and TAmiRNA now sheds light on the molecular mechanism behind a promising augmentation strategy: a single intraoperative dose of zoledronic acid. Background: A prior trial showed that a single systemic dose of zoledronic acid reduces retear rates in non-osteoporotic patients after rotator cuff repair. This follow-up study investigated the underlying biology by profiling circulating miRNAs linked to inflammation, fibrosis, and tendon-to-bone healing. Design: In a single-center, randomized, placebo-controlled, triple-blinded phase II trial, [...]

3 06, 2026

Why Spike-ins Are the Key to Reproducible Small RNA-seq Data

2026-06-03T10:23:09+02:00June 3rd, 2026|microRNA, microRNA services, microRNAs, miND, miND spike ins, miND spike-in, NGS, small RNA-sequencing, smallRNA|Comments Off on Why Spike-ins Are the Key to Reproducible Small RNA-seq Data

Reproducibility is one of the biggest challenges in small RNA sequencing – and at the same time one of the most critical requirements for valid biomarker studies. Whether you are comparing data across batches, running multi-laboratory studies, or working with disease cohorts that show shifts in global RNA content: without an external reference, there is no reliable anchor to make your data truly comparable. This is exactly where TAmiRNA's miND® Spike-ins come in. In our new miND® Spike-ins FAQ Guide, we answer the three most frequently asked questions we receive from researchers and CRO partners. How are spike-ins used? miND® Spike-ins are added directly to extracted RNA immediately before library preparation. This means they travel through the [...]

8 05, 2026

A New Milestone in EV-Based Therapies Research

2026-05-08T11:11:22+02:00May 8th, 2026|EV characterization, exosomes, extracellular vesicle, microRNA, microRNA services, microRNAs, Parkinson’s Disease|Comments Off on A New Milestone in EV-Based Therapies Research

A major hurdle in EV-based therapies is the "yield gap" — standard lab protocols simply cannot produce the volume of extracellular vesicles (EVs) required for clinical applications. However, scale-up could impact the quality and potency of therapeutic EVs. In our latest co-authored study published in 𝗦𝘁𝗲𝗺 𝗖𝗲𝗹𝗹𝘀 𝗧𝗿𝗮𝗻𝘀𝗹𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲, the teams at Exosomica, the Innovative Medicine Centre, the University of Latvia, alongside TAmiRNA scientists, addressed this challenge head-on. Together, we applied deep molecular fingerprinting and in vivo potency studies to validate a new large-scale production protocol for Parkinson’s Disease (PD) therapies. By leveraging our specialized transcriptomic and proteomic pipelines, we analyzed how production and purification methods shape the EV "message": ✅ 𝟯𝗗 𝘃𝘀. 𝟮𝗗 𝗖𝗼𝗺𝗽𝗮𝗿𝗶𝘀𝗼𝗻: Our analysis [...]

24 04, 2026

New publication in Biomaterials

2026-04-24T11:54:56+02:00April 24th, 2026|EV characterization, exosomes, extracellular vesicle, Macrophages, microRNA, microRNA services, microRNAs, RegenerativeMedicine, WoundHealing|Comments Off on New publication in Biomaterials

Huge congrats to Cansu Gorgun and the teams at Royal College of Surgeons in Ireland (RCSI) and Trinity College Dublin on their new publication in Biomaterials! This study is a fascinating look at how we can "train" macrophages to do two things at once. By reprogramming their metabolism, the team produced hybrid M1/M2 extracellular vesicles — a "dual-action" package that combines pro-inflammatory and pro-healing signals. We were lucky enough to support this work at 𝗧𝗔𝗺𝗶𝗥𝗡𝗔 by characterizing the EV miRNA cargo and looking into the functional implications of these hybrid vesicles. It’s a clever, elegant approach that opens new possibilities for smarter wound healing, tissue repair, and cell-free regenerative therapies. Fantastic work by everyone involved! TAmiRNA EV [...]

21 10, 2025

TAmiRNA @ Precision Medicine EV Forum

2025-10-21T11:40:23+02:00October 21st, 2025|biomarker, Biomarker Discovery, biomarkers, congress, exosomes, extracellular vesicle, isomiR, microRNA, microRNAs, small RNA-sequencing|Comments Off on TAmiRNA @ Precision Medicine EV Forum

TAmiRNA to Exhibit at the Precision Medicine EV Forum 2025 in Cambridge Vienna, October 2025 – TAmiRNA GmbH, a leading provider of extracellular vesicle (EV) transcriptomic services, is pleased to announce its participation as an exhibitor at the Precision Medicine EV Forum 2025, taking place in Cambridge, UK, from October 27th to 28th. The forum, a key event focused on the translational aspects of EV research, provides a platform for TAmiRNA to showcase its cutting-edge solutions for biomarker discovery and therapeutic development. Meet Our Experts Our CEO/CSO, Matthias Hackl, PhD, and Scientific Consultant, Magdalena Mecking, MSc, will be on-site to meet with researchers and industry leaders. They will be available to discuss how TAmiRNA’s proprietary workflows and [...]

14 10, 2025

hepatoMX Project Kickoff: TAmiRNA and You2Yourself Join Forces to Develop a Groundbreaking Urinary microRNA Diagnostic for Liver Disease

2025-10-14T08:25:31+02:00October 14th, 2025|biomarker, Biomarker Discovery, biomarkers, hepatoMX, Illumina NewSeq2000, microRNA services, microRNAs, miND, miND spike ins, NGS, sequencing, small RNA-sequencing, smallRNA|Comments Off on hepatoMX Project Kickoff: TAmiRNA and You2Yourself Join Forces to Develop a Groundbreaking Urinary microRNA Diagnostic for Liver Disease

We are excited to announce the official start of the EUREKA Eurostars project hepatoMX — a three-year collaboration between You2Yourself (Y2Y), a Dutch company specializing in small RNA-based early disease detection, and TAmiRNA GmbH, an Austrian SME with expertise in microRNA biomarker discovery and diagnostic test development (hepatomiR®). The project officially started on April 1, 2025, and aims to revolutionize the early detection of metabolic liver disease. The hepatoMX project will leverage TAmiRNA’s clinical expertise in liver diagnostics and Y2Y’s unique Urimon cohort that captures the dynamics of disease development to deliver a validated diagnostic test utilizing a proprietary urinary microRNA biomarker panel to identify early-stage liver disease in a simple and non-invasive manner. This innovative approach [...]

9 10, 2025

Microvascular microRNA Signatures in Sepsis: A High-Resolution View

2025-10-09T10:29:18+02:00October 9th, 2025|biomarker, Biomarker Discovery, biomarkers, Illumina NewSeq2000, laser microdissection (LMD), microRNA services, microRNAs, miND, miND spike ins, NGS, sequencing, small RNA-sequencing, smallRNA|Comments Off on Microvascular microRNA Signatures in Sepsis: A High-Resolution View

Sepsis drives profound microvascular injury, particularly in the kidney. But how do microRNAs (miRNAs) - the small regulators of gene expression - respond within distinct vascular compartments during this insult? A new study by Luxen et al.  published in Scientific Reports on October 2nd 2025 takes on this question using a clever methodological combination: laser microdissection (LMD) of microvascular subregions (arterioles, glomeruli, capillaries, postcapillary venules) followed by small RNA sequencing using TAmiRNA´s miND® workflow for highly sensitive and quantitative microRNA analysis. Why this approach matters Traditional microRNA profiling of whole tissues obscures spatial heterogeneity. With LMD, the authors could precisely isolate defined microvascular zones from kidney sections. Even with the tiny RNA yields from these isolated compartments, [...]

22 09, 2025

TAmiRNA @ GSEV 2025

2025-09-22T08:52:59+02:00September 22nd, 2025|biomarker, Biomarker Discovery, biomarkers, microRNAs, NGS, periprosthetic joint infections, small RNA-sequencing, Synovial fluid|Comments Off on TAmiRNA @ GSEV 2025

TAmiRNA Announces Gold Sponsorship of GSEV Autumn Meeting 2025 and Presentation by Matthias Hackl TAmiRNA, a pioneer in transcriptomics-based biomarker research, is proud to announce its participation as a Gold Sponsor at the GSEV Autumn Meeting 2025, hosted by the German Society for Extracellular Vesicles (GSEV). The annual conference will take place on September 25–26, 2025, at the Audimax of the University Hospital Essen. As part of the scientific program, Matthias Hackl (TAmiRNA) will deliver a presentation on Thursday, September 25, at 12:15 pm entitled: “Small RNA-sequencing (miND®) Enables Discovery of EV-specific MicroRNA Signatures to Support EV Therapeutics Development.” “Using miND®, we can robustly identify EV-specific microRNA signatures – a critical step toward enabling data-driven research and [...]

8 09, 2025

TAmiRNA @ EBJIS 2025

2025-09-17T11:35:44+02:00September 8th, 2025|biomarker, Biomarker Discovery, biomarkers, microRNAs, NGS, periprosthetic joint infections, small RNA-sequencing, Synovial fluid|Comments Off on TAmiRNA @ EBJIS 2025

TAmiRNA is proud to announce its participation at the upcoming European Bone and Joint Infection Society (EBJIS) Meeting 2025 in Ferrara, Italy. On Thursday, September 11, 2025 at 11:00 (Sala Emilia), Dr. Bernhard JH Frank will present groundbreaking new results from a collaborative study conducted with the Orthopaedic Hospital Speising and Dr. Jochen G. Hofstätter. The presentation is entitled: “Synovial fluid microRNA biomarkers enable accurate diagnosis of hip and knee periprosthetic joint infections.” Synovial fluid microRNA biomarkers for accurate PJI diagnosis Periprosthetic joint infection (PJI) is one of the most severe complications after hip and knee replacement surgery. Accurate and timely diagnosis remains a clinical challenge due to limited sensitivity and specificity of current diagnostic methods. In [...]

16 07, 2025

Webinar Announcement

2025-07-16T10:01:30+02:00July 16th, 2025|biomarker, Biomarker Discovery, biomarkers, FFPE, microRNAs, miND spike-in, NGS, small RNA-sequencing|Comments Off on Webinar Announcement

🔬 Join us For Our Upcoming Webinar with BioEcho Life Sciences In this session, we'll explore: Discover how TAmiRNA’s miND® small RNA-sequencing assay enables absolute quantification and quality control through synthetic spike-ins, making it a powerful tool for transcriptomic profiling in challenging samples. Learn about the BioEcho EchoLUTION FFPE RNA extraction kit, which preserves the integrity of small and large RNAs to maximize sensitivity and reproducibility in FFPE tissue analysis. See case studies demonstrating how integrated workflows—from RNA extraction to sequencing and bioinformatic analysis—support microRNA biomarker identification and mechanistic insights. Explore bioinformatic tools for analyzing small RNA-seq and multiomic datasets to uncover microRNA function, cellular origin, and regulatory networks. Whether you are working with archived tissue samples or liquid biopsies, [...]

Go to Top